Complement Therapeutics

Complement Therapeutics is a clinical-stage biotechnology company developing precision gene therapies for complement-mediated diseases, with a primary focus on ophthalmology. The company's lead asset, CTx001, is an AAV-based gene therapy designed to treat geographic atrophy secondary to dry age-related macular degeneration by delivering a DNA sequence that enables sustained local production of a complement regulatory protein. This approach aims to restore complement balance and prevent chronic inflammation and tissue damage in the eye through a single administration.